arrow
M

Masato Takahashi

based on the rules, a single department without a higher-level institution hierarchy stands alone. the institution name is extracted as is. radiological sciences
H指数:62
被引数:3.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study☆

艾瑞布林与紫杉烷类作为HER2阳性局部晚期或转移性乳腺癌患者的一线化疗联合双HER2阻断治疗的比较:JBCRG-M06/EMERALD研究的最终生存结果☆

2026-07-210
OAAI
Comparison of three arm-positioning techniques for minimizing motion artifacts in breast magnetic resonance imaging: a prospective volunteer study

比较三种臂位技术在减少乳腺磁共振成像运动伪影中的应用:一项前瞻性志愿者研究

2026-05-260
PRE
Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2− advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis

日本接受帕博西利+来曲唑一线治疗的ER+/HER2-晚期乳腺癌患者的总生存期及后续治疗模式:最终分析

2025-08-210
OAAI
Comparison of R2 value estimations using spin echo-multi echo and T2 mapping techniques for polymer gel dosimetry in radiotherapy

放疗聚合物凝胶剂量学中自旋回波-多回波与T2映射技术R2值估计的比较

2025-07-090
PRE
A search for μ+ → e+γ with the first dataset of the MEG II experiment (vol 84, 216, 2024)
2024-10-100
OA
Eribulin versus S-1 as fi rst or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a noninferiority, randomised, controlled, open-label, phase 3 trial
2024-08-010
OAAI
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
2024-06-243
OAAI
Overall survival (OS) and subsequent therapy patterns in Japanese patients with HR+/HER2-advanced breast cancer (ABC) treated with palbociclib (PAL) plus letrozole (LET) in first-line setting (1L)
2024-05-020
PRE
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
2024-05-020
PRE
Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)
2024-05-020
PRE
A search for μ+→e+ γ with the first dataset of the MEG II experiment
2024-03-0124
OA
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
2024-03-015
OAAI
Operation and performance of the MEG II detector
2024-02-265
OA